FAS and neoplasm: CRHR2 downregulation in vulvar cancerous and precancerous lesions is in accordance with the previous studies reporting that lack of CRHR2 receptor expression in colon cancer seems to (a) promote tumor growth and proliferation, maintaining a chronic inflammatory environment through continued activation of STAT3 [44] and (b) contribute to colon cancer cells’ resistance to apoptosis through FAS/FASL activation [45].